心筋梗塞の世界市場レポート 2025年

心筋梗塞市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.5％で29億4,000万米ドルに成長します。予測期間の成長は、心血管健康のための世界ヘルスイニシアチブ、再灌流療法へのアクセス拡大、心血管疾患のためのRNA治療薬、患者中心のケアモデル、微小血管機能不全へのフォーカス、バイオエレクトロニクス医療に起因しています。予測期間の主な動向には、心血管画像の進歩、心臓手術技術の進歩、遠隔医療の進歩、診断における人工知能の統合、リスク予測のためのデジタルバイオマーカーの革新、ヘルスケアデータセキュリティのためのブロックチェーン、AI主導の創薬、心臓リハビリテーション技術の革新などがあります。

心筋梗塞市場の予想成長率は、喫煙者の増加によって牽引されると予想されます。タバコ、葉巻、パイプなどによる喫煙を行う人は、タバコの煙に含まれる化学物質に身をさらすことになります。これらの物質は、静脈や動脈の血液を濃くしたり凝固させたりする可能性があり、心筋梗塞の原因となる閉塞につながります。2023年9月に英国国家統計局が発表したデータによると、英国の人口のうち25歳から34歳の喫煙者の割合が最も高く、2022年には16.3％、約140万人に上ることが明らかになった。これは、同じ年齢層の喫煙率が15.8％、約130万人であった前年より増加しました。その結果、喫煙者数の増加が心筋梗塞市場の成長を促進する重要な要因となっています。

心血管疾患の有病率の増加は、今後の心筋梗塞市場の成長を促進すると予測されています。心血管疾患には、心臓や血管に影響を及ぼすさまざまな疾患が含まれます。心筋梗塞の薬剤クラス別は、これらの疾患、特に心臓発作の後遺症を管理・治療するために使用されます。例えば、2024年9月、英国の心臓血管研究慈善団体であるBritish Heart Foundationが発表したデータによると、英国では約760万人が心臓および循環器疾患に罹患しており、その内訳は男性約400万人、女性約360万人です。これらの疾患は英国における全死亡の約27％を占め、年間17万人以上、毎日約480人が死亡しており、これは3分に1人が死亡していることになります。このように、心血管疾患の罹患率の増加が、心筋梗塞市場の成長に拍車をかけています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界心筋梗塞PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の心筋梗塞市場：成長率分析
• 世界の心筋梗塞市場の実績：規模と成長, 2019-2024
• 世界の心筋梗塞市場の予測：規模と成長, 2024-2029, 2034F
• 世界心筋梗塞総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の心筋梗塞市場薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗血小板薬
• 糖タンパク質IIbまたはIIIa阻害剤
• 抗血栓剤
• ベータ遮断薬
• 血管拡張薬
• アンジオテンシン変換酵素（ACE）阻害剤
• アンジオテンシン受容体遮断薬
• 鎮痛剤
• 血栓溶解剤
• 世界の心筋梗塞市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 注射可能
• 世界の心筋梗塞市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の心筋梗塞市場抗血小板薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アスピリン
• クロピドグレル
• チカグレロル
• 世界の心筋梗塞市場糖タンパク質IIbまたはIIIa阻害剤の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アブシキシマブ
• エプチフィバチド
• チロフィバン
• 世界の心筋梗塞市場抗血栓剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ヘパリン
• 直接経口抗凝固薬（DOAC）
• 世界の心筋梗塞市場、ベータ遮断薬の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• メトプロロール
• カルベジロール
• 世界の心筋梗塞市場血管拡張薬の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ニトログリセリン
• イソソルビドジニトラート
• 世界の心筋梗塞市場アンジオテンシン変換酵素（ACE）阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• リシノプリル
• エナラプリル
• 世界の心筋梗塞市場アンジオテンシン受容体遮断薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ロサルタン
• バルサルタン
• 世界の心筋梗塞市場、鎮痛剤の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• モルヒネ
• 非ステロイド性抗炎症薬（NSAID）
• 世界の心筋梗塞市場、血栓溶解剤の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アルテプラーゼ
• レテプラゼ

第7章 地域別・国別分析

• 世界の心筋梗塞市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の心筋梗塞市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 心筋梗塞市場：競合情勢
• 心筋梗塞市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sanofi SA
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Abbott Laboratories
• Boehringer Ingelheim GmbH
• Merck KGaA
• Daiichi Sankyo Co. Ltd.
• Apotex Inc.
• Siemens Healthcare Diagnostics Limited
• Annexin Pharmaceuticals AB
• Heartseed Inc.
• Par Pharmaceutical Companies Inc.
• Tenaya Therapeutics Inc.
• Idorsia Pharmaceuticals Ltd.
• Acesion Pharma ApS

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 心筋梗塞市場2029：新たな機会を提供する国
• 心筋梗塞市場2029：新たな機会を提供するセグメント
• 心筋梗塞市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Myocardial infarction, commonly known as a heart attack, poses a severe health risk, occurring when the blood flow to a segment of the heart muscle is obstructed, leading to tissue damage or death. This critical condition is often instigated by elevated levels of low-density lipoprotein, hypertension, and tobacco use.

Within the realm of myocardial infarction treatment, various drug classes play pivotal roles in managing and mitigating the condition's impact. These encompass antiplatelet agents, glycoprotein IIB/IIIA inhibitors, antithrombotic agents, beta-adrenergic blockers, vasodilators, angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor blockers, analgesics, and thrombolytics. Antiplatelet agents specifically target the prevention of blood clot formation by inhibiting platelet aggregation. Available in both oral and injectable formulations, these agents are accessible through a diverse range of distribution channels, including hospital pharmacies, retail pharmacies, and online platforms.

The myocardial infarction market research report is one of a series of new reports from The Business Research Company that provides myocardial infarction market statistics, including myocardial infarction industry global market size, regional shares, competitors with a myocardial infarction market share, detailed myocardial infarction market segments, market trends and opportunities, and any further data you may need to thrive in the myocardial infarction industry. This myocardial infarction market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The myocardial infarction market size has grown strongly in recent years. It will grow from $2.05 billion in 2024 to $2.2 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to the introduction of beta-blockers, the establishment of chest pain centers, thrombolytic therapies, personalized medicine approaches, and wearable cardiovascular devices

The myocardial infarction market size is expected to see strong growth in the next few years. It will grow to $2.94 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to global health initiatives for cardiovascular health, expanded access to reperfusion therapies, RNA therapeutics for cardiovascular diseases, patient-centered care models, focus on microvascular dysfunction, and bioelectronic medicine. Major trends in the forecast period include advancements in cardiovascular imaging, advancements in cardiac surgery techniques, advancements in telemedicine, integration of artificial intelligence in diagnosis, innovation of digital biomarkers for risk prediction, blockchain for healthcare data security, ai-driven drug discovery, and innovations in cardiac rehabilitation technologies.

The anticipated growth of the myocardial infarction market is expected to be driven by an increasing number of smokers. Individuals who engage in smoking, whether through cigarettes, cigars, or pipes, expose themselves to chemicals present in tobacco smoke. These substances have the potential to thicken and clot the blood in veins and arteries, leading to blockages that can result in myocardial infarction. A notable example is the data from the UK-based Office for National Statistics in September 2023, revealing that the segment of the UK population aged 25 to 34 years had the highest percentage of current smokers, accounting for 16.3% or approximately 1.4 million individuals in 2022. This marked an increase from the previous year, when the same age group had a smoking prevalence of 15.8%, encompassing around 1.3 million people. Consequently, the growing number of smokers is a significant factor propelling the growth of the myocardial infarction market.

The increasing prevalence of cardiovascular diseases is anticipated to drive the growth of the myocardial infarction market in the future. Cardiovascular diseases encompass a range of disorders that affect the heart and blood vessels. Drug classes for myocardial infarction are used to manage and treat these conditions, particularly in the aftermath of heart attacks. For example, in September 2024, data published by the British Heart Foundation, a UK-based cardiovascular research charity, indicated that approximately 7.6 million people in the UK are affected by heart and circulatory diseases, comprising about 4 million males and 3.6 million females. These conditions account for around 27% of all deaths in the UK, resulting in over 170,000 fatalities annually, or roughly 480 deaths each day, which translates to one death every three minutes. Thus, the rising incidence of cardiovascular diseases is fueling the growth of the myocardial infarction market.

Major companies in the myocardial infarction market are focused on developing novel drugs, such as anti-inflammatory drugs, for targeted cardiovascular inflammation treatment and to gain a competitive edge in the market. Anti-inflammatory drugs are medications that reduce inflammation, alleviating pain and swelling by targeting the body's immune response. For instance, in June 2023, Agepha Pharma, a Slovakia-based manufacturer of medical products, received FDA approval for its developed drug, Lodoco (colchicine), the first anti-inflammatory drug to target the underlying cause of atherosclerotic cardiovascular disease. Lodoco aims to reduce the risk of myocardial infarction, stroke, coronary revascularization, and cardiovascular death in adult patients. It can be used alone or with cholesterol-lowering medications. Lodoco, a reformulated low-dose colchicine, demonstrated a 31% reduction in the overall risk of cardiovascular death, myocardial infarction, stroke, or coronary revascularization in a clinical trial.

Major companies in the myocardial infarction market are focused on developing advanced devices that utilize technology, such as SmartAssist dual-sensor technology, to address acute right heart failure and to maximize their profits in the market. SmartAssist dual-sensor technology refers to a system equipped with two sensors designed to gather and monitor advanced metrics in a medical device. For instance, in October 2022, Abiomed, a US-based provider of medical technology, received FDA approval for its Impella RP Flex with SmartAssist. It is implanted via the internal jugular vein; it allows patient mobility and features dual-sensor technology for optimal patient management and weaning. The Impella RP platform includes percutaneous right heart mechanical circulatory support technologies designed for native heart recovery. Impella RP with SmartAssist has received approval from the U.S. FDA for the treatment of right heart failure or decompensation after procedures including left ventricular assist device implantation, myocardial infarction, and heart transplant.

In December 2022, Johnson & Johnson, a leading US-based healthcare products conglomerate, finalized the acquisition of Abiomed for a notable sum of $16.6 billion. This strategic acquisition positions Johnson & Johnson MedTech to integrate heart recovery solutions from Abiomed into its existing Biosense Webster electrophysiology division. By doing so, Johnson & Johnson aims to augment its offerings in the rapidly growing cardiovascular sector. Abiomed, renowned for its pioneering clinical research, specializes in the treatment of acute myocardial infarction, further enriching Johnson & Johnson's comprehensive cardiovascular solutions portfolio.

Major companies operating in the myocardial infarction market include Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, Boehringer Ingelheim GmbH, Merck KGaA, Daiichi Sankyo Co. Ltd., Apotex Inc., Siemens Healthcare Diagnostics Limited, Annexin Pharmaceuticals AB, Heartseed Inc., Par Pharmaceutical Companies Inc., Tenaya Therapeutics Inc., Idorsia Pharmaceuticals Ltd., Acesion Pharma ApS, Applied Therapeutics Inc., Athersys Inc., Cardurion Pharmaceuticals Inc., Verve Therapeutics Inc., Serca Pharmaceuticals AS

North America was the largest region in the myocardial infarction market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the myocardial infarction market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the myocardial infarction market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The myocardial infarction market consists of sales of heparin, bivalirudin, and enoxaparin. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Myocardial Infarction Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on myocardial infarction market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for myocardial infarction ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The myocardial infarction market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Antiplatelet Agents; Glycoprotein IIb Or IIIa Inhibitors; Antithrombotic Agents; Beta-Adrenergic Blockers; Vasodilators; Angiotensin-Converting Enzyme (ACE) Inhibitors; Angiotensin-Receptor Blockers; Analgesics; Thrombolytics
• 2) By Route Of Administration: Oral; Injectable
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Antiplatelet Agents: Aspirin; Clopidogrel; Ticagrelor
• 2) By Glycoprotein IIb Or IIIa Inhibitors: Abciximab; Eptifibatide; Tirofiban
• 3) By Antithrombotic Agents: Heparins; Direct Oral Anticoagulants (DOACs)
• 4) By Beta-Adrenergic Blockers: Metoprolol; Carvedilol
• 5) By Vasodilators: Nitroglycerin; Isosorbide Dinitrate
• 6) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Lisinopril; Enalapril
• 7) By Angiotensin-Receptor Blockers: Losartan; Valsartan
• 8) By Analgesics: Morphine; Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• 9) By Thrombolytics: Alteplase; Reteplase
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F. Hoffmann-La Roche Ltd.; Bayer AG; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Myocardial Infarction Market Characteristics

3. Myocardial Infarction Market Trends And Strategies

4. Myocardial Infarction Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Myocardial Infarction Growth Analysis And Strategic Analysis Framework

• 5.1. Global Myocardial Infarction PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Myocardial Infarction Market Growth Rate Analysis
• 5.4. Global Myocardial Infarction Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Myocardial Infarction Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Myocardial Infarction Total Addressable Market (TAM)

6. Myocardial Infarction Market Segmentation

• 6.1. Global Myocardial Infarction Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antiplatelet Agents
• Glycoprotein IIb Or IIIa Inhibitors
• Antithrombotic Agents
• Beta-Adrenergic Blockers
• Vasodilators
• Angiotensin-Converting Enzyme (ACE) Inhibitors
• Angiotensin-Receptor Blockers
• Analgesics
• Thrombolytics
• 6.2. Global Myocardial Infarction Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• 6.3. Global Myocardial Infarction Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.4. Global Myocardial Infarction Market, Sub-Segmentation Of Antiplatelet Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Aspirin
• Clopidogrel
• Ticagrelor
• 6.5. Global Myocardial Infarction Market, Sub-Segmentation Of Glycoprotein IIb Or IIIa Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Abciximab
• Eptifibatide
• Tirofiban
• 6.6. Global Myocardial Infarction Market, Sub-Segmentation Of Antithrombotic Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Heparins
• Direct Oral Anticoagulants (DOACs)
• 6.7. Global Myocardial Infarction Market, Sub-Segmentation Of Beta-Adrenergic Blockers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Metoprolol
• Carvedilol
• 6.8. Global Myocardial Infarction Market, Sub-Segmentation Of Vasodilators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nitroglycerin
• Isosorbide Dinitrate
• 6.9. Global Myocardial Infarction Market, Sub-Segmentation Of Angiotensin-Converting Enzyme (ACE) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lisinopril
• Enalapril
• 6.10. Global Myocardial Infarction Market, Sub-Segmentation Of Angiotensin-Receptor Blockers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Losartan
• Valsartan
• 6.11. Global Myocardial Infarction Market, Sub-Segmentation Of Analgesics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Morphine
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• 6.12. Global Myocardial Infarction Market, Sub-Segmentation Of Thrombolytics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Alteplase
• Reteplase

7. Myocardial Infarction Market Regional And Country Analysis

• 7.1. Global Myocardial Infarction Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Myocardial Infarction Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Myocardial Infarction Market

• 8.1. Asia-Pacific Myocardial Infarction Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Myocardial Infarction Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Myocardial Infarction Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Myocardial Infarction Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Myocardial Infarction Market

• 9.1. China Myocardial Infarction Market Overview
• 9.2. China Myocardial Infarction Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Myocardial Infarction Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Myocardial Infarction Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Myocardial Infarction Market

• 10.1. India Myocardial Infarction Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Myocardial Infarction Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Myocardial Infarction Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Myocardial Infarction Market

• 11.1. Japan Myocardial Infarction Market Overview
• 11.2. Japan Myocardial Infarction Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Myocardial Infarction Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Myocardial Infarction Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Myocardial Infarction Market

• 12.1. Australia Myocardial Infarction Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Myocardial Infarction Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Myocardial Infarction Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Myocardial Infarction Market

• 13.1. Indonesia Myocardial Infarction Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Myocardial Infarction Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Myocardial Infarction Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Myocardial Infarction Market

• 14.1. South Korea Myocardial Infarction Market Overview
• 14.2. South Korea Myocardial Infarction Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Myocardial Infarction Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Myocardial Infarction Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Myocardial Infarction Market

• 15.1. Western Europe Myocardial Infarction Market Overview
• 15.2. Western Europe Myocardial Infarction Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Myocardial Infarction Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Myocardial Infarction Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Myocardial Infarction Market

• 16.1. UK Myocardial Infarction Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Myocardial Infarction Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Myocardial Infarction Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Myocardial Infarction Market

• 17.1. Germany Myocardial Infarction Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Myocardial Infarction Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Myocardial Infarction Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Myocardial Infarction Market

• 18.1. France Myocardial Infarction Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Myocardial Infarction Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Myocardial Infarction Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Myocardial Infarction Market

• 19.1. Italy Myocardial Infarction Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Myocardial Infarction Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Myocardial Infarction Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Myocardial Infarction Market

• 20.1. Spain Myocardial Infarction Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Myocardial Infarction Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Myocardial Infarction Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Myocardial Infarction Market

• 21.1. Eastern Europe Myocardial Infarction Market Overview
• 21.2. Eastern Europe Myocardial Infarction Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Myocardial Infarction Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Myocardial Infarction Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Myocardial Infarction Market

• 22.1. Russia Myocardial Infarction Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Myocardial Infarction Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Myocardial Infarction Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Myocardial Infarction Market

• 23.1. North America Myocardial Infarction Market Overview
• 23.2. North America Myocardial Infarction Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Myocardial Infarction Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Myocardial Infarction Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Myocardial Infarction Market

• 24.1. USA Myocardial Infarction Market Overview
• 24.2. USA Myocardial Infarction Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Myocardial Infarction Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Myocardial Infarction Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Myocardial Infarction Market

• 25.1. Canada Myocardial Infarction Market Overview
• 25.2. Canada Myocardial Infarction Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Myocardial Infarction Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Myocardial Infarction Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Myocardial Infarction Market

• 26.1. South America Myocardial Infarction Market Overview
• 26.2. South America Myocardial Infarction Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Myocardial Infarction Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Myocardial Infarction Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Myocardial Infarction Market

• 27.1. Brazil Myocardial Infarction Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Myocardial Infarction Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Myocardial Infarction Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Myocardial Infarction Market

• 28.1. Middle East Myocardial Infarction Market Overview
• 28.2. Middle East Myocardial Infarction Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Myocardial Infarction Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Myocardial Infarction Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Myocardial Infarction Market

• 29.1. Africa Myocardial Infarction Market Overview
• 29.2. Africa Myocardial Infarction Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Myocardial Infarction Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Myocardial Infarction Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Myocardial Infarction Market Competitive Landscape And Company Profiles

• 30.1. Myocardial Infarction Market Competitive Landscape
• 30.2. Myocardial Infarction Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Myocardial Infarction Market Other Major And Innovative Companies

• 31.1. Sanofi SA
• 31.2. Bristol-Myers Squibb Company
• 31.3. AstraZeneca PLC
• 31.4. Abbott Laboratories
• 31.5. Boehringer Ingelheim GmbH
• 31.6. Merck KGaA
• 31.7. Daiichi Sankyo Co. Ltd.
• 31.8. Apotex Inc.
• 31.9. Siemens Healthcare Diagnostics Limited
• 31.10. Annexin Pharmaceuticals AB
• 31.11. Heartseed Inc.
• 31.12. Par Pharmaceutical Companies Inc.
• 31.13. Tenaya Therapeutics Inc.
• 31.14. Idorsia Pharmaceuticals Ltd.
• 31.15. Acesion Pharma ApS

32. Global Myocardial Infarction Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Myocardial Infarction Market

34. Recent Developments In The Myocardial Infarction Market

35. Myocardial Infarction Market High Potential Countries, Segments and Strategies

• 35.1 Myocardial Infarction Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Myocardial Infarction Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Myocardial Infarction Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer